ClinVar Miner

Submissions for variant NM_003289.4(TPM2):c.40G>C (p.Asp14His)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV005134880 SCV005761904 uncertain significance Arthrogryposis, distal, type 1A 2024-07-16 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 14 of the TPM2 protein (p.Asp14His). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TPM2-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Asp14 amino acid residue in TPM2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22980765, 24692096; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.